Muvalaplin

N/A

Report date: 2025/09/01 20:01:25
NME

Base Information

Drug NameMuvalaplin
Drug Alias NameLY-3473329
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApolipoprotein(a) inhibitors
TargetsApolipoprotein(a)
Therapy Area/IndicationsLipid Metabolism DisordersAtherosclerosisCardiovascular Diseases +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Inactive CompaniesLilly Del Caribe Inc
Active IndicationsLipid Metabolism DisordersAtherosclerosisRenal Insufficiency
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A